- Home
- CAN vs ZNTL Comparison
CAN vs ZNTL Comparison
Compare CAN & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAN
- ZNTL
- Stock Information
- Founded
- CAN 2013
- ZNTL 2014
- Country
- CAN Singapore
- ZNTL United States
- Employees
- CAN N/A
- ZNTL N/A
- Industry
- CAN Semiconductors
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- CAN Technology
- ZNTL Health Care
- Exchange
- CAN Nasdaq
- ZNTL Nasdaq
- Market Cap
- CAN 280.5M
- ZNTL 238.2M
- IPO Year
- CAN 2019
- ZNTL 2020
- Fundamental
- Price
- CAN $0.99
- ZNTL $3.20
- Analyst Decision
- CAN Strong Buy
- ZNTL Buy
- Analyst Count
- CAN 4
- ZNTL 7
- Target Price
- CAN $3.38
- ZNTL $10.86
- AVG Volume (30 Days)
- CAN 5.2M
- ZNTL 1.2M
- Earning Date
- CAN 11-26-2024
- ZNTL 11-04-2024
- Dividend Yield
- CAN N/A
- ZNTL N/A
- EPS Growth
- CAN N/A
- ZNTL N/A
- EPS
- CAN N/A
- ZNTL N/A
- Revenue
- CAN $189,341,000.00
- ZNTL $40,560,000.00
- Revenue This Year
- CAN $24.54
- ZNTL N/A
- Revenue Next Year
- CAN $43.73
- ZNTL N/A
- P/E Ratio
- CAN N/A
- ZNTL N/A
- Revenue Growth
- CAN N/A
- ZNTL N/A
- 52 Week Low
- CAN $0.72
- ZNTL $2.83
- 52 Week High
- CAN $3.50
- ZNTL $18.24
- Technical
- Relative Strength Index (RSI)
- CAN 50.09
- ZNTL 46.94
- Support Level
- CAN $0.95
- ZNTL $2.92
- Resistance Level
- CAN $1.02
- ZNTL $3.06
- Average True Range (ATR)
- CAN 0.05
- ZNTL 0.17
- MACD
- CAN -0.00
- ZNTL -0.00
- Stochastic Oscillator
- CAN 41.96
- ZNTL 46.97
About CAN Canaan Inc.
Canaan Inc is a developer of supercomputing chips and the manufacturer of digital blockchain computing equipment as well as the supplier of the overall scheme for computer software and hardware of digital blockchain. The revenues of the company are derived from the sales of Bitcoin mining machines and related parts.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.